PE20070169A1 - Derivados del 4,5-diarilpirrol como antagonistas de receptores cb1 - Google Patents
Derivados del 4,5-diarilpirrol como antagonistas de receptores cb1Info
- Publication number
- PE20070169A1 PE20070169A1 PE2006000721A PE2006000721A PE20070169A1 PE 20070169 A1 PE20070169 A1 PE 20070169A1 PE 2006000721 A PE2006000721 A PE 2006000721A PE 2006000721 A PE2006000721 A PE 2006000721A PE 20070169 A1 PE20070169 A1 PE 20070169A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- alkyl
- pyrrol
- phenyl
- trifluoromethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/323—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
SE REFIERE A DERIVADOS DE 4,5-DIARIL-2-AMINOMETILPIRROL DE FORMULA (I), DONDE X ES -CO-, -SO2-, -CO-N(R6); R1 ES H O ALQUILO(C1-C4); R2 ES ALQUILO(C1-C12), CARBOCICLICO NO AROMATICO(C3-C12), METILO, FENILO, BENCILO, ENTRE OTROS OPCIONALMENTE SUSTITUIDOS; R3 ES ALQUILO(C1-C5) O CICLOALQUILO(C3-C7); R4 ES FENILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO(C1-C4), ALCOXI(C1-C4), ENTRE OTROS; R5 ES FENILO OPCIONALMENTE SUSTITUIDO CON HALOGENO, ALQUILO(C1-C4), CIANO, TRIFLUOROMETILO, ENTRE OTROS; R6 ES H O ALQUILO(C1-C4). SON PREFERIDOS: N-((5-(4-CLOROFENIL)-4-(2,4-DICLOROFENIL)-1-METIL-1H-PIRROL-2-IL)METIL-4-(TRIFLUOROMETIL)BENZAMIDA, 3-CLORO-N-((5-(4-CLOROFENIL)-4-(2,4-DICLOROFENIL)-1-METIL-1H-PIRROL-2-IL)METIL)-BENCENOSULFONAMIDA, N-((5-(4-CLOROFENIL)-4-(2,4-DICLOROFENIL)-1-METIL-1H-PIRROL-2-IL)METIL-N'-(3-TRIFLUOROMETIL)FENIL)UREA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. LOS COMPUESTOS SON ANTAGONISTAS DE LOS RECEPTORES CB1 DE LOS CANABINOIDES LOCALIZADOS A NIVEL CENTRAL Y/O PERIFERICO Y SON UTILES PARA EL TRATAMIENTO DE TRANSTORNOS SIQUIATRICOS, COMO ANSIEDAD, DEPRESION, INSOMNIO, SICOSIS EN GENERAL
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0506609A FR2887548B1 (fr) | 2005-06-27 | 2005-06-27 | Derives de 4,5-diarylpyrrole, leur preparation et leur application en therapeutique |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20070169A1 true PE20070169A1 (es) | 2007-03-07 |
Family
ID=35884019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2006000721A PE20070169A1 (es) | 2005-06-27 | 2006-06-23 | Derivados del 4,5-diarilpirrol como antagonistas de receptores cb1 |
Country Status (28)
Country | Link |
---|---|
US (1) | US7618995B2 (es) |
EP (1) | EP1899298B1 (es) |
JP (1) | JP5142152B2 (es) |
KR (1) | KR20080019641A (es) |
CN (1) | CN101208300A (es) |
AR (1) | AR057401A1 (es) |
AT (1) | ATE478045T1 (es) |
AU (1) | AU2006263781A1 (es) |
BR (1) | BRPI0612497A2 (es) |
CA (1) | CA2610805A1 (es) |
CR (1) | CR9565A (es) |
DE (1) | DE602006016285D1 (es) |
DO (1) | DOP2006000133A (es) |
EA (1) | EA200800149A1 (es) |
EC (1) | ECSP078009A (es) |
FR (1) | FR2887548B1 (es) |
IL (1) | IL188032A0 (es) |
MA (1) | MA29559B1 (es) |
MX (1) | MX2007016383A (es) |
NO (1) | NO20080458L (es) |
NZ (1) | NZ564195A (es) |
PA (1) | PA8681701A1 (es) |
PE (1) | PE20070169A1 (es) |
SV (1) | SV2007002580A (es) |
TN (1) | TNSN07439A1 (es) |
TW (1) | TW200740753A (es) |
UY (1) | UY29631A1 (es) |
WO (1) | WO2007000505A2 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2874012B1 (fr) * | 2004-08-09 | 2008-08-22 | Sanofi Synthelabo | Derives de pyrrole, leur preparation et leur utlisation en therapeutique |
EP2300427A1 (en) * | 2008-05-05 | 2011-03-30 | Amgen Inc. | Urea compounds as gamma secretase modulators |
FR2930939B1 (fr) * | 2008-05-09 | 2010-07-30 | Sanofi Aventis | Derives de pyrrole, leur preparation et leur application en therapeutique |
GB201103419D0 (es) | 2011-02-28 | 2011-04-13 | Univ Aberdeen | |
JP6423372B2 (ja) | 2013-02-28 | 2018-11-14 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 強力なrock1およびrock2阻害剤としてのフェニルピラゾール誘導体 |
AR094929A1 (es) | 2013-02-28 | 2015-09-09 | Bristol Myers Squibb Co | Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2 |
CH710832A1 (de) | 2015-03-09 | 2016-09-15 | Kaba Ag | Programmierbarer Schliesszylinder. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4335136A (en) * | 1980-04-18 | 1982-06-15 | E. I. Du Pont De Nemours And Company | Anti-inflammatory 4,5-diaryl-α-(polyfluoroalkyl)-1H-pyrrole-2-methanamines |
FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
ATE250576T1 (de) * | 1996-12-10 | 2003-10-15 | Searle & Co | Substituierte pyrrolylverbindungen zur behandlung von entzündungen |
GB0230088D0 (en) * | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
FR2874012B1 (fr) * | 2004-08-09 | 2008-08-22 | Sanofi Synthelabo | Derives de pyrrole, leur preparation et leur utlisation en therapeutique |
-
2005
- 2005-06-27 FR FR0506609A patent/FR2887548B1/fr not_active Expired - Fee Related
-
2006
- 2006-06-12 DO DO2006000133A patent/DOP2006000133A/es unknown
- 2006-06-22 EP EP06764809A patent/EP1899298B1/fr active Active
- 2006-06-22 CN CNA2006800230670A patent/CN101208300A/zh active Pending
- 2006-06-22 AT AT06764809T patent/ATE478045T1/de not_active IP Right Cessation
- 2006-06-22 EA EA200800149A patent/EA200800149A1/ru unknown
- 2006-06-22 JP JP2008518897A patent/JP5142152B2/ja not_active Expired - Fee Related
- 2006-06-22 KR KR1020077030262A patent/KR20080019641A/ko not_active Withdrawn
- 2006-06-22 CA CA002610805A patent/CA2610805A1/fr not_active Abandoned
- 2006-06-22 DE DE602006016285T patent/DE602006016285D1/de active Active
- 2006-06-22 BR BRPI0612497-6A patent/BRPI0612497A2/pt not_active Application Discontinuation
- 2006-06-22 AU AU2006263781A patent/AU2006263781A1/en not_active Abandoned
- 2006-06-22 MX MX2007016383A patent/MX2007016383A/es not_active Application Discontinuation
- 2006-06-22 NZ NZ564195A patent/NZ564195A/en unknown
- 2006-06-22 WO PCT/FR2006/001416 patent/WO2007000505A2/fr active Application Filing
- 2006-06-22 PA PA20068681701A patent/PA8681701A1/es unknown
- 2006-06-23 AR ARP060102708A patent/AR057401A1/es unknown
- 2006-06-23 PE PE2006000721A patent/PE20070169A1/es not_active Application Discontinuation
- 2006-06-23 SV SV2006002580A patent/SV2007002580A/es not_active Application Discontinuation
- 2006-06-26 TW TW095122990A patent/TW200740753A/zh unknown
- 2006-06-27 UY UY29631A patent/UY29631A1/es unknown
-
2007
- 2007-11-26 TN TNP2007000439A patent/TNSN07439A1/en unknown
- 2007-12-06 CR CR9565A patent/CR9565A/es not_active Application Discontinuation
- 2007-12-07 US US11/952,224 patent/US7618995B2/en not_active Expired - Fee Related
- 2007-12-10 IL IL188032A patent/IL188032A0/en unknown
- 2007-12-13 EC EC2007008009A patent/ECSP078009A/es unknown
- 2007-12-24 MA MA30500A patent/MA29559B1/fr unknown
-
2008
- 2008-01-24 NO NO20080458A patent/NO20080458L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
UY29631A1 (es) | 2007-01-31 |
US20080176924A1 (en) | 2008-07-24 |
CA2610805A1 (fr) | 2007-01-04 |
FR2887548A1 (fr) | 2006-12-29 |
BRPI0612497A2 (pt) | 2010-11-23 |
ATE478045T1 (de) | 2010-09-15 |
US7618995B2 (en) | 2009-11-17 |
EP1899298A2 (fr) | 2008-03-19 |
FR2887548B1 (fr) | 2007-09-21 |
CR9565A (es) | 2008-04-10 |
MX2007016383A (es) | 2008-03-07 |
ECSP078009A (es) | 2008-01-23 |
KR20080019641A (ko) | 2008-03-04 |
WO2007000505A2 (fr) | 2007-01-04 |
EA200800149A1 (ru) | 2008-04-28 |
NO20080458L (no) | 2008-01-24 |
SV2007002580A (es) | 2007-02-19 |
DE602006016285D1 (de) | 2010-09-30 |
IL188032A0 (en) | 2008-03-20 |
DOP2006000133A (es) | 2007-02-28 |
AU2006263781A1 (en) | 2007-01-04 |
WO2007000505A3 (fr) | 2007-11-15 |
JP5142152B2 (ja) | 2013-02-13 |
EP1899298B1 (fr) | 2010-08-18 |
CN101208300A (zh) | 2008-06-25 |
MA29559B1 (fr) | 2008-06-02 |
AR057401A1 (es) | 2007-12-05 |
NZ564195A (en) | 2010-01-29 |
TNSN07439A1 (en) | 2009-03-17 |
JP2008546829A (ja) | 2008-12-25 |
PA8681701A1 (es) | 2007-01-17 |
TW200740753A (en) | 2007-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20090509A1 (es) | El uso de derivados de benzamida para el tratamiento de transtornos del snc | |
PE20070169A1 (es) | Derivados del 4,5-diarilpirrol como antagonistas de receptores cb1 | |
PE20121050A1 (es) | Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog | |
PE20061038A1 (es) | Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion | |
PE20081530A1 (es) | Nuevos compuestos 617 | |
PE20061150A1 (es) | Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1) | |
PE20081315A1 (es) | Derivados de benzimidazol como antagonistas de vr-1 | |
PE20001483A1 (es) | Acidos oxamicos y derivados como ligandos de receptores tiroideos | |
AR072952A1 (es) | Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso | |
PE20040590A1 (es) | Composiciones de pirrolotriazina anilina como inhibidores de cinasa | |
PE20090617A1 (es) | Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa | |
PE20081314A1 (es) | COMPUESTOS TRICICLICOS FUSIONADOS NO ESTEROIDALES COMO MODULADORES DEL RECEPTOR GLUCOCORTICOIDE, AP-1 Y/O ACTIVIDAD NF-kB | |
PE20040599A1 (es) | Amidas sustituidas como moduladores del receptor cannabinoide-1 (cb1) | |
PE20020753A1 (es) | Heteroaromaticos fusionados como activadores de la glucoquinasa | |
AR052156A1 (es) | Fenil-metanonas bi- y triciclicas sustituidas para el tratamiento de trastornos neurologicos y neuropsiquiatricos | |
PE20090417A1 (es) | Compuestos de piperazina con accion herbicida | |
BRPI0507506A (pt) | compostos | |
PE20081755A1 (es) | Nuevas 2-aminooxazolinas como ligandos taar1 | |
PE20091431A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
PE20071224A1 (es) | Derivados de aminometilpiridina como antagonistas de los receptores cannabinoides 1 (cb1) | |
PE20070829A1 (es) | Inhibidores cetp heterociclicos | |
PE20070069A1 (es) | Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a | |
ATE418548T1 (de) | Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten | |
MXPA05007115A (es) | Nuevos agonistas inversos del receptor cb 1. | |
PE20080345A1 (es) | Derivados de piperazina como agonistas del receptor de gpr38 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |